Published Work

Glecaprevir/pibrentasvir for the treatment of hepatitis C virus infection among active drug users

Glecaprevir/pibrentasvir for the treatment of hepatitis C virus infection among active drug users: the GRAND PLAN study Presented at the...

Sofosbuvir/velpatasvir (S/V) for the treatment of chronic HCV in active drug users: the CHIME study

Presented at the Canadian Liver Meeting. February 28- March 1, Montreal, Canada, 2020.

Overdose events among active drug users successfully treated for HCV: the impact of homelessness.

Presented at the Canadian Liver Meeting. February 28- March 1, Montreal, Canada, 2020.

Towards the elimination of HCV in British Columbia: a strategy to address the “messy middle”

Presented at the International Viral Hepatitis Elimination, November 22-23, Amsterdam, Netherlands, 2019

Effectiveness of sofosbuvir/velpatasvir and elbasvir/grazoprevir for the treatment of HCV genotype 1

Effectiveness of sofosbuvir/velpatasvir and elbasvir/grazoprevir for the treatment of HCV genotype 1 infection in a real-world cohort...

Real-World Efficacy of Salvage Therapies for the Treatment of Chronic Hepatitis C Virus Infection...

Real-world efficacy of salvage therapies for the treatment of chronic hepatitis C virus infection in treatment experienced people who...

Long-term follow-up of people who use drugs (PWUD) following successful HCV therapy...

Long-term follow-up of people who use drugs (PWUD) following successful HCV therapy: drug use patterns and maintenance of cure Presented...

COVID-19 & Sports